Skip to main content
Fig. 4 | Malaria Journal

Fig. 4

From: Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission

Fig. 4

Effects of immunization against rPb51 on asexual proliferation, gametocytogenesis and host survival. a Growth curves of P. berghei in normal BALB/c mice (no immunization) and mice immunized with the control Trx/His/S-tag protein (control) or rPb51. Normal group exhibited 1.82-fold higher parasitaemia than the rPb51-immunized group on day 9 post-infection. b Gametocytaemia in mice without immunization (normal), immunized with Trx/His/S-tag protein (control) or rPb51. Note that gametocytaemia on day 3 was not statistically different among the immunization groups. c Survival of mice in different treatment groups. Mice in the rPb51-immunized group survived 6 days longer than the normal group and 7 days longer than control group. The data represent three separate experiments (six mice/group). Error bars indicate mean ± SD. *P < 0.05, **P < 0.01 (Student’s t test)

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us